CLSN Celsion Corporation

0.25
+0.02  (9.51%)
Previous Close 0.23
Open 0.23
Price To book 0.56
Market Cap 6.52M
Shares 26,078,000
Volume 5,618,154
Short Ratio 1.46
Av. Daily Volume 1,513,620

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Final data released December 2015
ThermoDox - Dignity
Recurrent Chest Wall Breast Cancer (RCWBC)
Failed to meet primary endpoint. New Phase 3 trial initiated, with enrollment to be completed early 2018 with first interim efficacy endpoint due 4Q 2018.
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
Phase 1b interim data released January 17, 2016 with final data due 2Q 2017.
GEN-1 OVATION
Ovarian cancer

Latest News

  1. Celsion Corp. Cancer Medications Insider Buying and Analysis
  2. CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  3. Celsion Corporation Announces $5.0 Million Public Offering
  4. CELSION CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  5. ETFs with exposure to Celsion Corp. : January 19, 2017
  6. Celsion to Present Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium
  7. Celsion Corporation Announces Issuance of Two New Patents for ThermoDox®
  8. Celsion Announces Continuing Positive Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients
  9. CELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
  10. ETFs with exposure to Celsion Corp. : December 22, 2016
  11. CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  12. Celsion Corporation Announces $1.8 Million Registered Direct Offering
  13. Celsion Corporation Announces Progress with ThermoDox® Development Efforts in China and Asia Pacific
  14. Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer
  15. Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III OPTIMA Study of ThermoDox® for Primary Liver Cancer
  16. Celsion Corporation Announces Presentation of Results from Independent NIH Analysis of ThermoDox® plus Optimized RFA for the Treatment of Primary Liver Cancer at the 2016 RSNA Annual Meeting
  17. CELSION CORP Financials
  18. ETFs with exposure to Celsion Corp. : November 16, 2016
  19. Celsion Corp. :CLSN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016
  20. CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits